{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-105024","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.953031+00:00","generated_at":"2026-05-17T17:19:56.375857+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Kura Oncology Q2 net loss widens to $66.1M; FDA sets Nov 30 PDUFA for ziftomenib NDA","bullets":["Net loss $66.1M in Q2 2025 vs $50.8M in Q2 2024; collaboration revenue $15.3M from Kyowa Kirin.","FDA Priority Review for ziftomenib NDA; PDUFA target action date Nov 30, 2025.","Cash, equivalents and investments $630.7M as of June 30; expected to fund operations into 2027, plus Kyowa Kirin funding.","Phase 3 KOMET-017 trials and first KO-2806/FTI data expected in 2H 2025 at ESMO."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-105024","json":"https://secwatch.observer/filing/0000950170-25-105024.json","markdown":"https://secwatch.observer/filing/0000950170-25-105024.md","text":"https://secwatch.observer/filing/0000950170-25-105024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000095017025105024/0000950170-25-105024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000095017025105024/kura-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:19:56.375857+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}